Instead, data on the effect of GLP-1R agonists regarding patients with reduced left ventricular function or heart failure are still controversial, as semaglutide has been found to reduce HF and the risk of cardiovascular events in non-diabetic patients with obesity, whereas liraglutide and exenatide seem to increase hospitalization in diabetic patients with HF and a reduced ejection fraction [13,14,15]. The gene discussed is GLP1R; the disease is hydrops fetalis.